

CV date	24/02/2023
---------	------------

Part A. PERSONAL INFORMATION

First and FAMILY name	José Manuel PADRÓN CARRILLO		
Researcher IDs	ORCID	0000-0001-6268-6552	
	Researcher ID	H-5240-2011	
Author ID:	José M. Padrón	Scopus ID	7003856521
		Google Scholar	EDAYWm0AAAAJ

A.1. Current position

Institution	Universidad de La Laguna (ULL)		
Department	Instituto Universitario de Bio-Orgánica Antonio González (IUBO-AG)		
Address and Country	Astrofísico Francisco Sánchez 2, 38206 La Laguna, Canary Islands		
Phone number	+34 922316502 ext. 6126	E-mail	jmpadron@ull.es
Current position	Full Professor (Head of BioLab)	From	14/12/2020
UNESCO spec. code	239001	Design, Synthesis and Study of New Drugs	
Keywords	Anticancer drugs; Molecular pharmacology; Drug discovery; Solid tumors; Mechanisms of action; Early pharmacological profiling		

A.2. Previous positions

Period	Position/Institution/Country/Interruption cause
2019-present *	Secretary of IUBO-AG / Universidad de La Laguna / Spain
2018-2020 *	Science Communications Manager COST Action CA17104 - STRATAGEM
2017-2020	Associate Professor / Universidad de La Laguna / Spain
2013-2015 *	Director of Technology Transfer Office / Universidad de La Laguna / Spain
2011-2017	Tenured Lecturer / Universidad de La Laguna / Spain
2007-2011	Ramón y Cajal Researcher / Universidad de La Laguna / Spain
2004-2005	Postdoc Researcher / Instituto Canario de Investigación del Cáncer / Spain
2001-2003	Senior Scientist / DSM Deretil / (Almería) Spain
1998-2001	Postdoc Researcher / DSM Research / The Netherlands
1997-1998	Postdoc Researcher / Academic Hospital Free University / The Netherlands
1992-1996	PhD Student (FPI Grant holder) / Universidad de La Laguna / Spain

* Institutional appointment

A.3. Education

Degree	Institution	Year
PhD Pharmacy (<i>cum laude</i>)	Universidad de La Laguna	1996
Diploma in Public Health	Escuela Nacional de Sanidad	1994
BSc Pharmacy (<i>honors</i>)	Universidad de La Laguna	1991

A.4. Articles, h-index and six-year research merits

A.4.1. Scientific articles: **193** SJR (Q1: 133), **9** non-SJR, **1** Book chapter

Database	Last access	h-index	Total citations	Since 2018
Google Scholar	01/02/2023	33	3840	1886
Scopus	01/02/2023	30	3082	1490
Web of Science	01/02/2023	29	2976	1424

A.4.2. Six-year research merit traits: **4** (1993-1998, 1999-2006, 2007-2012, 2013-2018)

Part B. CV SUMMARY

PROFILE: A Senior Researcher with extensive experience in Research Project Management within the public and the private sectors. A Highly Collaborative Scientist at the international level with active participation in European Research Networks. Former TTO Director with experience and expertise of technology transfer at the academic environment. A Full Professor with teaching skills at the international level. A PhD Degree coupled with a proven track record of publications, patents and contracts with companies. A highly effective negotiator and communicator with great people skills along with strong leadership, problem solving and decision-making abilities and an eye for the bottom-line.

ACCOMPLISHMENTS, COLLABORATIONS & LEADERSHIP: I completed my PhD under the supervision of Prof. Víctor S. Martín in the asymmetric synthesis of a variety of biologically active molecules such as lipidic α -amino acids and derivatives, and fused cyclic ethers. I moved to the Vrije Universiteit medisch centrum in Amsterdam (NL), for postdoctoral research with Prof. G. J. Peters getting insight in the molecular pharmacology of anticancer drugs. In 1998, I joined DSM Research in Geleen (NL) to work for three years on the enantioselective membrane separation of pharmaceutically relevant carboxylic acids with Prof. J. G. de Vries. Afterwards, I worked from 2001 to 2003 in Almería (ES) at Deretil in the production of β -lactam antibiotics. Upon return to the Canary Islands in 2004, I started a screening program aimed at the discovery of new anticancer substances and I successfully established BioLab, an independent research group at ULL. Overall, I co-authored 186 articles in scientific journals collected in the SJR, have participated in numerous congresses with over 200 presentations, co-inventor of 4 granted patents and 1 under evaluation, PI of various competitive funding projects, joined numerous (inter-)national projects, and signed contracts with companies.

I have established long-term open collaborations with several academic groups in Europe, Latin-American and Asia. I participate in diverse International Scientific Committees, such as EORTC – Pharmacology and Molecular Mechanisms Group (PAMM) and the Management Committee of COST Actions CM1106, CA15106, CA15135 and CA17104.

At BioLab, I have clustered a solid and experienced group of multidisciplinary scientists with expertise in chemistry, biochemistry, pharmacy, engineering and microbiology to develop realistic and collaborative research programs on Molecular Pharmacology, Medicinal Chemistry, Pharmaceutical Technology, and Bioprospection of Endemic Plants in the Canary Islands to find therapeutic solutions to human diseases, with a particular focus on -but not limited to- cancer.

CONTRIBUTIONS TO SOCIETY: I regularly participate in talks to students from local high schools. I have been interviewed in diverse local and national media to comment on our research and the results. I was appointed Science Communication Manager of COST Action CA17104 and managed all issues related to dissemination of the results of the network including building and keeping updated web pages and social media accounts. I use social media to disseminate the results of our group (@BioLabULL) and from our Institute (@iuboag). Recently, I got the approval of ULL to implement the Transfer Unit *BioLAB* (*BioLab for Business*) in order to ease collaborations with the private sector.

TRAINING AND EVALUATION: I have overseen numerous end-of-degree and end-of-master projects, two completed PhD thesis, supervised several postdocs, and over 60 scientific visitors from Europe, Africa and Latin America. I participate as a member of the editorial board of diverse scientific journals.

I have participated as an Advisory Board Member of BioVaria from 2015 to 2017. BioVaria targets technology scouts, business developers and investors highlighting commercially attractive licensing opportunities and promising startups from across Europe. Recently, I have been appointed *Intellectual property/tech transfer coordinator* of COST Action CA21116. I am an international evaluator for the National Science Centre (NCN, Poland), National Council for Science and Technology (CONACYT, Mexico), Fund for Scientific and Technological Research (FONCYT, Argentina), and National Research and Development Agency (ANID, Chile).

OTHER CONTRIBUTIONS: Extensive (inter-)national teaching experience at graduate and postgraduate level.

Part C. RELEVANT MERITS

C.1. Publications (full list at <https://scholar.google.com/citations?user=EDAYWm0AAAAJ>)

C.1.1. Articles published as journal covers

					
<i>J. Org. Chem.</i> 2014 , 79(15), 6775-6782	<i>Eur. J. Inorg. Chem.</i> 2018 , 2018(43), 4684-4688	<i>J. Molec. Clin. Med.</i> 2018 , 1(2), 195-200	<i>Tetrahedron Lett.</i> 2019 , 60(25), 1640-1642	<i>Eur. J. Org. Chem.</i> 2021 , 2021(12), 1859-1863	<i>Cryst. Eng. Comm.</i> 2022 , 24(29), 5194-5214

C.1.2. Selected articles (5) as corresponding author

- Hicke FJ, Puerta A, Dinić J, Pešić M, **Padrón JM**, López Ó, Fernández-Bolaños JG. Straightforward access to novel mitochondriotropics derived from 2-arylethanol as potent and selective antiproliferative agents (2022) *European Journal of Medicinal Chemistry*, 228, 113980. DOI: 10.1016/j.ejmech.2021.113980
- Guerra WD, Lucena-Agell D, Hortigüela R, Rossi RA, Fernando Díaz J, **Padrón JM**, Barolo SM. Design, synthesis, and in vitro evaluation of tubulin-targeting dibenzothiazines with antiproliferative activity as a novel heterocycle building block (2021) *ChemMedChem*, 16(19), 3003-3016. DOI: 10.1002/cmdc.202100383
- Ahuja-Casarín AI, Merino-Montiel P, Vega-Baez JL, Montiel-Smith S, Fernandes MX, Lagunes I, Maya I, **Padrón JM**, López Ó, Fernández-Bolaños JG. Tuning the activity of iminosugars: novel *N*-alkylated deoxynojirimycin derivatives as strong BuChE inhibitors (2021) *Journal of Enzyme Inhibition and Medicinal Chemistry*, 36(1), 138-146. DOI: 10.1080/14756366.2020.1847101
- Dinić J, Ríos-Luci C, Karpaviciene I, Cikotiene I, Fernandes MX, Pešić M, **Padrón JM**. CKT0353, a novel microtubule targeting agent, overcomes paclitaxel induced resistance in cancer cells (2020) *Investigational New Drugs*, 38(3), 584-598. DOI: 10.1007/s10637-019-00803-6
- Lagunes I, Begines P, Silva A, Galán AR, Puerta A, Fernandes MX, Maya I, Fernández-Bolaños JG, López Ó, **Padrón JM**. Selenocoumarins as new multitarget

antiproliferative agents: Synthesis, biological evaluation and in silico calculations (2019) *European Journal of Medicinal Chemistry*, 179, 493-501. DOI: 10.1016/j.ejmech.2019.06.073

C.2. Major research projects and grants

C.2.1. Principal investigator

PID2021-123059OB-I00 - Targeting cell metabolism in pancreatic ductal adenocarcinoma (STARVING). MICINN. 01/09/2022-31/08/2026. 108.900,00 €.

ProID2020010101 - New therapeutic strategies for the treatment of pancreatic cancer (TheraPanc). ACIISI. 01/01/2020-30/09/2022. 70.000,00 €.

EIS 2020 06_ULL - Early pharmacological profile of marine natural products of the Canarian biodiversity (FARMACAN). ACIISI. 01/01/2020-30/09/2021. 146.000,00 €.

EIN2019-102928 - Preparación de la acción MSC-ITN Multitargeted therapies against pancreatic ductal adenocarcinoma (PANCNET). 01/06/2019-31/05/2022. 16.200,00 €.

PI11/00840 - Mechanism of action of novel antitumor compounds disruptors of cell division. Instituto de Salud Carlos III (Acción Estratégica en Salud 2011). 01/01/2012-31/12/2014. 86.212,50 €.

SAF2011-15072-E - EORTC-PAMM Group Winter Meeting. Ministerio de Ciencia e Innovación (Acciones Complementarias 2011). 01/01/2012-30/06/2013. 10.000,00 €.

PI43/09 - Desarrollo de nuevos fármacos antibacterianos y antifúngicos derivados de estructuras privilegiadas de origen marino. FUNCIS. 2010-2012. 20.000,00 €.

PI2007/021 - Mecanismos de acción de la actividad citotóxica y/o estrogénica de fitoestrógenos naturales, lípidos bioactivos y sus análogos sintéticos. ACIISI. 2009-2012. 34.000,00 €.

PI35/06 - Desarrollo de nuevos fármacos antitumorales derivados de estructuras privilegiadas de origen marino. FUNCIS. 2008-2011. 30.000,00 €.

RYC-2006-001716 - Diseño, síntesis y actividad antitumoral de nuevos análogos de estructuras privilegiadas de origen marino: espisulosina/esfingosina, éteres cíclicos halogenados y β -hidroxicetonas α,β -insaturadas. MEC (Programa Ramón y Cajal). 01/01/2007-30/06/2011. 15.000,00 €.

C.2.2. Member of the research team

COST Actions: **CA21116, CA20113, CA17104, CA15135, CA15106, CM1106.**

EU: **FP7-REGPOT-2012-2013-1:316137, FP4-TMR FMRX980233, FP3-HCM CHRX930288, 05/MAC/2.3/C14**

National: **PGC2018-094503-B-C22, FCT-13-7158, A/032351/10, A/025750/09, CTQ2008-06806-C02-01/BQU, RD06/0020/1046, CTQ2005-09074-C02-01/BQU, PI01/06, A/6972/06, A/4014/05, PPQ2002-04361-C04-02, GC02460601, PB95-0751, PB92-0849, PB89-0402**

Latin America: **CB-2015 256495, FCE_1_2014_1_103499, Grupo 1063 Proyecto 981, CB-2014 240329, 2014-1D4-01, 2013-1D4-003, 2012-2013-1D3-4, CB-2012 181820, FCE-2-2011-1-5717, PROIPRO P20106**

C.3. Participation in International Scientific Committees

2007-present *Full member.* EORTC – Pharmacology and Molecular Mechanisms Group (PAMM)

2012-2016 *Management Committee.* COST CM1106 – Chemical Approaches to Targeting Drug Resistance in Cancer Stem Cells (StemChem)

2015-2017 *Advisory Board.* BioVaria.

2016-2020 *Management Committee.* COST CA15106 – C-H Activation in Organic Synthesis (CHAOS)

2016-2020 *Management Committee.* COST CA15135 – Multi-target paradigm for innovative ligand identification in the drug discovery process (MuTaLig)

2018-2022 *Management Committee.* COST CA17104 – New diagnostic and therapeutic tools against multidrug resistant tumors (STRATAGEM)

C.4. Research Awards

2005 Academia Iberoamericana de Farmacia

2005 Instituto Canario de Investigación del Cáncer: 1st Young Cancer Investigators Award